AI Drug Company Overstated Prospects, Securities Class Alleges
BRIDGEPORT, Conn. — A company harnessing artificial intelligence (AI) to identify new uses for existing medications continued to release positive statements about its upcoming drug and failed to disclose that it...To view the full article, register now.
Already a subscriber? Click here to view full article